Ifp Advisors, Inc Aeglea Bio Therapeutics, Inc. Transaction History

Ifp Advisors, Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Sep 06, 2022	BUY	$0.5 - $2.66 $1,430 - $7,607	2,860 New	2,860 $29,000
Q2 2022 Aug 12, 2022	SELL	$0.5 - $2.66 $1,430 - $7,607	-2,860 Closed	0 $0
Q1 2022 Sep 06, 2022	SELL	$1.87 - $4.77 $224 - $572	-120 Reduced 4.03%	2,860 $6,000
Q3 2021 Oct 06, 2021	SELL	$6.03 - $7.95 $6,030 - $7,950	-1,000 Reduced 25.13%	2,980 $24,000
Q2 2021 Jul 13, 2021	BUY	$6.32 - $8.38 $3,160 - $4,190	500 Added 14.37%	3,980 $27,000
Q1 2021 Apr 30, 2021	BUY	$6.76 - $8.57 $6,760 - $8,570	1,000 Added 40.32%	3,480 $28,000
Q2 2020 Aug 05, 2020	SELL	$4.01 - $11.04 $2,005 - $5,520	-500 Reduced 16.78%	2,480 $23,000
Q1 2020 May 12, 2020	BUY	$3.51 - $8.48 $1,755 - $4,240	500 Added 20.16%	2,980 $16,000
Q3 2019 Nov 07, 2019	BUY	$6.42 - $9.0 $15,921 - $22,320	2,480 New	2,480 $19,000
Q1 2019 May 15, 2019	SELL	$7.6 - $9.4 $912 - $1,128	-120 Closed	0 $0
Q4 2018 Jan 23, 2019	BUY	$6.51 - $10.19 $781 - $1,222	120 New	120 $0
Q3 2018 Oct 25, 2018	SELL	$8.24 - $11.0 $4,120 - $5,500	-500 Closed	0 $0
Q4 2017 Jan 24, 2018	SELL	$4.0 - $5.98 $9,440 - $14,112	-2,360 Reduced 82.52%	500 $0
Q4 2016 Jun 03, 2019	BUY	N/A	2,860	2,860 $12,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.